Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Titan BiotechBOM:524717 +2.84%51 Days Payable is 41.39 as of Mar. 2026, which is 110% above its 10-year median of 19.69. GuruFocus rates BOM:524717 with a GF Score™ of 51/100 and a GF Value™ of ₹144.93 (Significantly Overvalued). The stock has 2 warning signs investors should review. Among 701 Biotechnology companies, Titan Biotech ranks worse than 84.88% on this metric.
The historical rank and industry rank for Titan Biotech's Days Payable or its related term are showing as below:
BOM:524717'
s Days Payable Range Over the Past 10 Years
Min: 11.81 Med: 19.69 Max: 26.1
Current: 25.09
During the past 13 years, Titan Biotech's highest Days Payable was 26.10. The lowest was 11.81. And the median was 19.69.
BOM:524717's Days Payable is ranked worse than 84.88% of 701
companies
in the Biotechnology industry
Industry Median: 112.84
vs BOM:524717: 25.09
Titan Biotech's Days Payable
increased
from Mar. 2025 (31.71) to Mar. 2026 (41.39).
It may suggest that Titan Biotechdelayed paying its suppliers.
Titan Biotech Days Payable Related Terms
Titan Biotech Days Payable Historical Data
* Premium members only.
The historical data trend for Titan Biotech's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:524717 vs VRTX, REGN, ALNY: Days Payable Comparison
For the Biotechnology subindustry, Titan Biotech's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Titan Biotech Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Titan Biotech's Days Payable distribution charts can be found below:
* The bar in red indicates where Titan Biotech's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Titan Biotech's Days Payable for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Titan Biotech (BOM:524717) has a Days Payable of 41.39 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Titan Biotech and its competitors. This is 110% above median its historical median of 19.69. Over the past decade, Titan Biotech's Days Payable has ranged from 11.81 to 26.10. According to the industry distribution chart, Titan Biotech ranks #595 out of 701 companies in the Biotechnology industry, placing it in the top 84.9%.
Is Titan Biotech's Days Payable too high?
Titan Biotech's current Days Payable of 41.39 is 110% above median its 10-year median of 19.69. Over the past 10 years, this metric has ranged from a low of 11.81 to a high of 26.10. The Biotechnology industry median Days Payable is 112.84. Titan Biotech's value of 41.39 is 63.3% below this industry median. Based on the distribution chart, Titan Biotech ranks #595 out of 701 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Titan Biotech has a GF Score™ of 51/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Titan Biotech's Days Payable compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Titan Biotech ranks #595 out of 701 companies for Days Payable. This places Titan Biotech in the lower half of its industry. The industry median Days Payable is 112.84. Titan Biotech's value of 41.39 is 63.3% below this benchmark. Historically, Titan Biotech's own Days Payable has ranged from 11.81 to 26.10 over the past decade. While the company's 10-year median is 19.69 vs. the industry median of 112.84, Titan Biotech has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 112.84, based on 701 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Titan Biotech's current Days Payable of 41.39 is 63.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Titan Biotech and its competitors. For the Biotechnology industry, the median Days Payable is 112.84 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Titan Biotech's current Days Payable is 41.39, which is 110% above median its own 10-year median of 19.69. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Titan Biotech stock overvalued right now?
Based on GuruFocus' analysis, Titan Biotech (BOM:524717) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹144.93, compared to a current price of ₹418.70 — trading 188.9% above its estimated fair value. The current Days Payable is 41.39, which is 110% above median its 10-year median of 19.69 and 63.3% below the Biotechnology industry median of 112.84. Titan Biotech's overall GF Score™ is 51/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Titan Biotech (BOM:524717), the current Days Payable is 41.39 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Titan Biotech (BOM:524717) Overvalued in 2026?
Based on GuruFocus' analysis, Titan Biotech stock appears to be overvalued.
The current stock price of ₹418.70 is trading 188.9% above its estimated GF Value™ of ₹144.93.
GuruFocus considers Titan Biotech to be Significantly Overvalued.
Key valuation signals for BOM:524717:
Days Payable: 41.39 (110% above median its 10-year median of 19.69)
GF Value™: ₹144.93 vs. price of ₹418.70 (188.9% above fair value)
Industry Position: 63.3% below the Biotechnology median (#595 of 701)
No single metric tells the full story. See the BOM:524717 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Titan Biotech Ltd is a manufacturer and exporter of biological products. It manufactures biological products such as peptone, malt extract, yeast extract, liver extract, bile extract, culture media, laboratory chemicals, plant growth promoters, and others. The biological products have applications in the field of pharmaceutical, nutraceutical, food and beverages, biotechnology and fermentation, cosmetic, veterinary and animal feed, agriculture industries, and others. The company's business activity falls within a single primary business segment, which is the business of Biological Products. The firm sells its products in India and also exports internationally, of which the majority of the revenue is derived from the sales made in India.
51GF Score
Get the complete analysis for BOM:524717
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:524717 has been successfully added to your 
